Cystic Fibrosis
Cystic fibrosis (CF) is the second most common life-shortening, childhood onset inherited disorder in the U.S. behind sickle cell anemia. Approximately 30,000 people in the U.S. have CF. CF is characterized by the production of abnormally thick and sticky mucus which most frequently obstructs the lungs, leading to progressive chronic and life-threatening lung infections, and the pancreatic ducts, preventing normal digestion and malnutrition. The median age of survival for is only 35 years. CF mortality results primarily from chronic unresolved lung infections due to impaired airway mucus clearance.
Effective CF respiratory medications and therapy should reduce infection and assist in the elimination of excessive mucus where bacteria thrive. Prevention of infectious exacerbations that lead to lung tissue destruction and decline in lung function is the key to improving long term outcomes in CF patients. Aerolytic™ is unique; it is a truncated natural human protein that is targeted to normalize epithelial salt balance to improve mucus hydration and clearance properties.
